Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100
Debt
Debt-to-Equity Ratio0.79
Current Ratio1.98
Quick Ratio1.38
Price-To-Earnings
Trailing P/E Ratio-3.23
Forward P/E Ratio-4.06
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.31 million
Price / Sales1.77
Cash FlowN/A
Price / CashN/A
Book Value$2.89 per share
Price / Book2.25
Profitability
EPS (Most Recent Fiscal Year)($2.01)
Net Income$-27,290,000.00
Net Margins-41.50%
Return on Equity-61.61%
Return on Assets-26.55%
Miscellaneous
Employees213
Outstanding Shares17,510,000
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery Inc (NASDAQ:APEN) issued its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.07. The biotechnology company earned $15.74 million during the quarter, compared to analyst estimates of $16 million. Apollo Endosurgery had a negative return on equity of 61.61% and a negative net margin of 41.50%. View Apollo Endosurgery's Earnings History.
What price target have analysts set for APEN?
4 brokers have issued twelve-month price targets for Apollo Endosurgery's shares. Their predictions range from $8.00 to $12.00. On average, they expect Apollo Endosurgery's stock price to reach $10.25 in the next twelve months. View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (5/2/2018)
- 2. Northland Securities analysts commented, "We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera." (2/8/2018)
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Anika Therapeutics (ANIK), Utah Medical Products (UTMD), Antares Pharma (ATRS), GenMark Diagnostics (GNMK), Inovio Pharmaceuticals (INO), Orthopediatrics (KIDS), T2 Biosystems (TTOO), Westaim (WEDXF), Accuray (ARAY), Cytosorbents (CTSO), Nuvectra (NVTR), RenovaCare (RCAR), Pulse Biosciences (PLSE), Iradimed (IRMD) and SeaSpine (SPNE).
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 55)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
- Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
Has Apollo Endosurgery been receiving favorable news coverage?
Media stories about APEN stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Apollo Endosurgery's major shareholders?
Apollo Endosurgery's stock is owned by a number of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (1.89%), NJ State Employees Deferred Compensation Plan (0.90%), University of Texas Texas AM Investment Managment Co. (0.68%) and Dimensional Fund Advisors LP (0.35%). Company insiders that own Apollo Endosurgery stock include A/S Novo, Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Institutional Ownership Trends for Apollo Endosurgery.
Which major investors are selling Apollo Endosurgery stock?
Which major investors are buying Apollo Endosurgery stock?
APEN stock was purchased by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan, Dimensional Fund Advisors LP and Russell Investments Group Ltd.. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Insider Buying and Selling for Apollo Endosurgery.
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $6.50.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $115.74 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
